Informations

Prostate cancer is one of the most common malignancies affecting the male genitourinary system, and in China, a significant proportion of newly diagnosed patients present with advanced disease. Since late-stage prostate cancer is symptomatic and not curable, alleviating symptoms, delaying disease progression, and improving quality of life have always been priorities for both patients and…

CAR-T Therapy in GI Cancers Adoptive T-cell therapies, including CAR-T, TCR-T, and tumor-infiltrating lymphocyte (TIL) therapies, are being explored for their potential to improve outcomes in GI cancers. CAR-T therapy,…

Prostate cancer is one of the most common malignancies threatening men’s health worldwide. With population aging and lifestyle changes, the incidence of prostate cancer in China has been steadily increasing in recent years. As an early-stage disease, localized prostate cancer generally has a favorable prognosis, with curative potential through comprehensive treatment primarily centered on local…

Breast cancer has become one of the most common malignancies among women, with triple-negative breast cancer (TNBC) being considered the most aggressive subtype due to its historically poor prognosis. Looking back at 2024, significant research breakthroughs have emerged in both early-stage and advanced TNBC treatment, covering chemotherapy, targeted therapy, immunotherapy, and antibody-drug conjugates (ADCs). Many…

Bladder cancer is one of the most common malignancies of the urinary system, posing a serious threat to public health in China. For patients with localized disease, repeated intravesical treatments and follow-up procedures require frequent hospital visits, while those who undergo surgery often face the lifelong challenge of urinary diversion. Patients with inoperable advanced bladder…

At the San Antonio Breast Cancer Symposium (SABCS 2024), Dr. Maria Margarete Karsten and her team presented groundbreaking findings from the PRO B trial, a multicenter study evaluating the impact of alert-based patient-reported outcome (PRO) monitoring in metastatic breast cancer patients.